Population-Level Trends in Attention-Deficit/Hyperactivity Disorder Medication Prescribing

This cross-sectional study describes changes in prescription rates for attention-deficit/hyperactivity (ADHD) disorder medication in Ontario from 2015 to 2023.

Corresponding Author: Daniel T. Myran, MD, MPH, North York General Hospital, 4001 Leslie St, Toronto, ON M2K 1E1, Canada (dmyran@ohri.ca).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.